References 169 [17] Fallingborg J, Christensen LA, Jacobsen BA, Rasmussen SN, Dig. Dis. Sci. 1993, 38, 1989–1993. [18] Roediger W, Lawson MJ, Kwok V, Grant AK, Pannall PR, J. Clin. Pathol. 1984, 37, 704–707. [19] Sasaki Y, Hada R, Nakajima H, Fukuda S, Munakata A, Am. J. Gastroenterol. 1997, 92, 114–118. [20] Leopold CS, Eikeler D, J. <strong>Drug</strong> Target. 1998, 6, 85–94. [21] Leopold CS, Eikeler D, <strong>Drug</strong> Dev. Ind. Pharm. 2000, 26, 1239–1246. [22] Wunderlich J-C, Schick U, Werry J, Freidenreich J, International Patent WO 93/10767, 1993. [23] Pitzele BS, Jones PH, US Patent 4,374,932, 1983. [24] Leopold CS, Pharmazie in unserer Zeit 1997, 26, 289–298. [25] Friend DR, Tozer TN, J. Control. Rel. 1992, 19, 109–120. [26] Friend DR, STP Pharma Sci. 1995, 5, 70–76. [27] Hirayama F, Minami K, Uekama K, J. Pharm. Pharmacol. 1996, 48, 27–31. [28] Hirayama F, Minami K, Uekama K, Proc. 2nd World Meeting APGI/APV 1998, 2, 935–936. [29] Harboe E, Larsen C, Johansen M, Olesen HP, Pharm. Res. 1989, 6, 919–923. [30] Larsen C, Harboe E, Johansen M, Olesen HP, Pharm. Res. 1989, 6, 995–999. [31] Larsen C, Jensen BH, Olesen HP, Acta Pharm. Nord. 1991, 3, 71–76. [32] McLeod AD, In: Oral Colon-specific <strong>Drug</strong> Delivery (Ed. Friend DR), pp. 213–231. CRC Press, Boca Raton, 1992. [33] McLeod AD, Tolentino L, Tozer TN, Biopharm. <strong>Drug</strong> Dispos. 1994, 15, 151–161. [34] McLeod AD, Fedorak RN, Friend DR, Tozer TN, Cui NR, Gastroenterology 1994, 106, 405–413. [35] Leopold CS, Friend DR, Int. J. Pharm. 1995, 126, 139–145. [36] Leopold CS, Friend DR, J. Pharmacokinet. Biopharm. 1995, 23, 397–406. [37] McLeod AD, Tozer TN, In: Oral Colon-specific <strong>Drug</strong> Delivery (Ed. Friend DR), pp. 85–114. CRC Press, Boca Raton, 1992. [38] Fedorak RN, Haeberlin B, Empey LR, Cui N, Nolen H, III, Jewell LD, Friend DR, Gastroenterology 1995, 108, 1688–1699. [39] Tozer TN, Rigod J, McLeod AD, Gungon R, Hoag MK, Friend DR, Pharm. Res. 1991, 8, 445–454. [40] Saffran M, Kumar GS, Savariar C, Burnham JC, Williams F, Neckers DC, Science 1986, 233, 1081–1084. [41] Saffran M, Kumar GS, Neckers DC, Peña J, Jones RH, Field JB, Biochem. Soc. Trans. 1990, 18, 752–754. [42] Van den Mooter G, Samyn C, Kinget R, Int. J. Pharm. 1992, 87, 37–46. [43] Van den Mooter G, Samyn C, Kinget R, Pharm. Res. 1994, 11, 1737–1741. [44] Van den Mooter G, Samyn C, Kinget R, Pharm. Res. 1995, 12, 244–247. [45] Van den Mooter G, Maris B, Samyn C, Augustijns P, Kinget R, J. Pharm. Sci. 1997, 86, 1321–1327. [46] Lloyd AW, Martin GP, Soozandehfar SH, Int. J. Pharm. 1994, 106, 255–260. [47] Schacht E, Wilding I, International Patent WO 91/11175, 1991. [48] Bauer KH, Deutsche Patentschrift 42 09 160, 1993. [49] Betzing J, Bauer KH, Pharm. Ztg. Wiss. 1992, 137, 131–134. [50] Sarlikiotis AW, Bauer KH, Pharm. Ind. 1992, 54, 873–880. [51] Sekigawa F, Onda Y, US Patent 5,217,720, 1993. [52] Kesselhut JF, Bauer KH, Pharmazie 1995, 50, 263–269. [53] Watanabe S, Kawai H, Katsuma M, Fukui M, International Patent WO 95/28963, 1995. [54] Siefke V, Weckenmann H, Bauer K, Proc. Int. Symp. Control. Rel. Bioact. Mater. 1993, 20, 182–183. [55] Lehmann K, Dreher KD, Proc. Int. Symp. Control. Rel. Bioact. Mater. 1991, 18, 331–332. [56] Milojevic S, Newton JM, Cummings JH, Gibson GR, Bothman RL, Ring SG, Allwood MC, Stockham M, STP Pharma Sci. 1995, 5, 47–53. [57] Siew LF, Newton JM, Pharm. Res. 1997, 14 (11 Suppl.), S-658. [58] Macleod GS, Fell JT, Collett JH, Int. J. Pharm. 1997, 157, 53–60. [59] Wakerly Z, Fell JT, Attwood D, Parkins D, Pharm. Res. 1996, 13, 1210–1212. [60] Wakerly Z, Fell JT, Attwood D, Parkins D, Int. J. Pharm. 1997, 153, 219–224. [61] Vervoort L, Kinget R, Int. J. Pharm. 1996, 129, 185–190. [62] Krishnaiah YSR, Satyanarayana S, Prasad YVR, Rao SN, Int. J. Pharm. 1998, 171, 137–146. [63] Krishnaiah YSR, Satyanarayana S, Prasad YVR, <strong>Drug</strong> Dev. Industr. Pharm. 1999, 25, 651–657. [64] Rubinstein A, Radai R, Eur. J. Pharm. Biopharm. 1995, 41, 291–295. [65] Chen RH, Tsaih ML, Lin WC, Carbohydr. Polymers 1996, 31, 141–148. [66] Tozaki H, Komoike J, Tada C, Maruyama T, Terabe A, Suzuki T, Yamamoto A, Muranishi S, J. Pharm. Sci. 1997, 86, 1016–1021. [67] Brøndsted H, Andersen C, Hovgaard L, J. Control. Rel. 1998, 53, 7–13.
170 6 A Practical Approach in the Design of Colon-specific <strong>Drug</strong> Delivery Systems [68] Brøndsted H, Kopecek J, Pharm. Res. 1992, 9, 1540–1545. [69] Kakoulides EP, Smart JD, Tsibouklis J, J. Control. Rel. 1998, 54, 95–109. [70] Samyn C, Kalala W, Van den Mooter G, Kinget R, Int. J. Pharm. 1995, 121, 211–216. [71] Bragger JL, Lloyd AW, Soozandehfar SH, Bloomfield SC, Marriott C, Martin GP, Int. J. Pharm. 1997, 157, 61–71. [72] Van den Mooter G, Offringa M, Kalala W, Samyn C, Kinget R, STP Pharma Sci. 1995, 5, 36–40. [73] Chiu HC, Hsiue GH, Lee YP, Huang LW, J. Biomater. Sci. 1999, 10, 591–608. [74] Hovgaard L, Brøndsted H, J. Control. Rel. 1995, 36, 159–166. [75] Rubinstein A, Nakar D, Sintov A, Int. J. Pharm. 1992, 84, 141–150. [76] Rubinstein A, Nakar D, Sintov A, Pharm. Res. 1992, 9, 276–278. [77] Rubinstein A, Gliko-Kabir I, STP Pharma Sci. 1995, 5, 41–46. [78] Rubinstein A, Gliko-Kabir I, Penhasi A, Yagen B, Proc. Int. Symp. Control. Rel. Bioact. Mater. 1997, 24, 839–840. [79] Ashford M, Fell J, Attwood D, Sharma H, Woodhead P, J. Control. Rel. 1993, 26, 213–220. [80] Ashford M, Fell J, Attwood D, Sharma H, Woodhead P, J. Control. Rel. 1994, 30, 225–232. [81] Rubinstein A, Radai R, Ezra M, Pathak S, Rokem JS, Pharm. Res. 1993, 10, 258–263. [82] Wakerly Z, Fell J, Attwood D, Parkins D, J. Pharm. Pharmacol. 1997, 49, 622–625. [83] Vervoort L, Van den Mooter G, Augustijns P, Bousson R, Toppet S, Kinget R, Pharm. Res. 1997, 14, 1730–1737. [84] Vervoort L, Van den Mooter G, Augustijns P, Kinget R, Int. J. Pharm. 1998, 172, 127–135. [85] Vervoort L, Rombaut P, Van den Mooter G, Augustijns P, Kinget R, Int. J. Pharm. 1998, 172, 137–145. [86] Ishibashi T, Pitcairn GR, Yoshino H, Mizobe M, Wilding IR, J. Pharm. Sci. 1998, 87, 531–535. [87] Ishibashi T, Hatano H, Kobayashi M, Mizobe M, Yoshino H, Int. J. Pharm. 1998, 168, 31–40. [88] Ishibashi T, Hatano H, Kobayashi M, Mizobe M, Yoshino H, J. Control. Rel. 1999, 57, 45–53. [89] Yamada A, Wato T, Uchida N, Fujisawa M, Takama S, Inamoto Y, US Patent 5,395,628, 1995. [90] Narisawa S, Nagata M, Danyoshi C, Yoshino H, Murata K, Hirakawa Y, Noda K, Pharm. Res. 1994, 11, 111–116. [91] Narisawa S, Nagata M, Hirakawa Y, Kobayashi M, Yoshino H, J. Pharm. Sci. 1996, 85, 184–188. [92] Abramowitz R, Ranadive S, Jain NB, Varia SA, Pharm. Res. 1997, 14 (11 Suppl.), S656. [93] Gazzaniga A, Sangalli ME, Giordano F, Eur. J. Pharm. Biopharm. 1994, 40, 246–250. [94] Ueda S, Ibuki R, Kawamura A, Murata S, Takahashi T, Kimura S, Hata T, J. <strong>Drug</strong> Target. 1994, 2, 133–140. [95] Ueda S, Hata T, Asakura S, Yamaguchi H, Kotani M, Ueda Y, J. <strong>Drug</strong> Target. 1994, 2, 35–44. [96] Pozzi F, Furlani P, Gazzaniga A, Davis SS, Wilding IR, J. Control. Rel. 1994, 31, 99–108. [97] Steed KP, Hooper G, Monti N, Strolin Benedetti M, Fornasini G, Wilding IR, J. Control. Rel. 1997, 49, 115–122. [98] Wilding IR, Davis SS, Pozzi F, Furlani P, Gazzaniga A, Int. J. Pharm. 1994, 111, 99–102. [99] Binns J, Stevens HNE, McEwen J, Pritchard G, Brewer FM, Clarke A, Johnson ES, McMillan I, J. Control. Rel. 1996, 38, 151–158. [100] Hegarty M, Atkins G, International Patent WO 95/10263, 1995. [101] Kraeling MEK, Ritschel WA, Methods Find. Exp. Clin. Pharmacol. 1992, 14, 199–209. [102] Rao SS, Ritschel WA, Int. J. Pharm. 1992, 86, 35–41. [103] Shah NH, Phuapradit W, Railkar A, US Patent 5,482,718, 1996. [104] Muraoka M, Hu ZP, Shimokawa T, Sekino S, Kurogoshi R, Kuboi Y, Yoshikawa Y, Takada K, J. Control. Rel. 1998, 52, 119–129. [105] Takaya T, Sawada K, Suzuki H, Funaoka A, Matsuda KI, Takada K, J. <strong>Drug</strong> Target. 1997, 4, 271–276. [106] Takaya T, Niwa K, Muraoka M, Ogita I, Nagai N, Yano R, Kimura G, Yoshikawa Y, Yoshikawa H, Takada K, J. Contr. Rel. 1998, 50, 111–122. [107] Adkin DA, Kenyon CJ, Lerner EI, Landau I, Strauss E, Caron D, Penhasi A, Rubinstein A, Wilding IR, Pharm. Res. 1997, 14, 103–107. [108] Weitschies W, Kotitz R, Cordini D, Trahms L, J. Pharm. Sci. 1997, 86, 1218–1222. [109] Weitschies W, Cardini D, Karaus M, Trahms L, Semmler W, Pharmazie 1999, 54, 426–430. [110] Tozer TN, Friend DR, McLeod AD, STP Pharma Sci. 1995, 5, 5–12.
- Page 1 and 2:
Drug Targeting Organ-Specific Strat
- Page 3 and 4:
Drug Targeting Organ-Specific Strat
- Page 5 and 6:
Preface Drug Targeting Organ-Specif
- Page 7 and 8:
Foreword Drug Targeting Organ-Speci
- Page 9 and 10:
X List of Contributors Henderik W.
- Page 11 and 12:
XII List of Contributors Grietje Mo
- Page 13 and 14:
Contents Drug Targeting Organ-Speci
- Page 15 and 16:
Contents XVII 3 Pulmonary Drug Deli
- Page 17 and 18:
Contents XIX 5.2.1.6 Identification
- Page 19 and 20:
Contents XXI 7.5 In Vitro Technique
- Page 21 and 22:
Contents XXIII 9.4 Tumour Vasculatu
- Page 23 and 24:
Contents XXV 12.8. Tissue Slices fr
- Page 25 and 26:
Drug Targeting Organ-Specific Strat
- Page 27 and 28:
Dexa dexamethasone DIVEMA divinyl e
- Page 29 and 30:
LRP lung resistance related protein
- Page 31 and 32:
ROS reactive oxygen species RSV res
- Page 33 and 34:
Index a ADEPT 217, 224, 268, 291 ad
- Page 35 and 36:
e E. coli expression system 292 eff
- Page 37 and 38:
polymers, soluble 4, 218 - dendrime
- Page 39 and 40:
2 1 Drug Targeting: Basic Concepts
- Page 41 and 42:
4 1 Drug Targeting: Basic Concepts
- Page 43 and 44:
6 1 Drug Targeting: Basic Concepts
- Page 45 and 46:
8 1 Drug Targeting: Basic Concepts
- Page 47 and 48:
10 1 Drug Targeting: Basic Concepts
- Page 49 and 50:
12 1 Drug Targeting: Basic Concepts
- Page 51 and 52:
14 1 Drug Targeting: Basic Concepts
- Page 53 and 54:
16 1 Drug Targeting: Basic Concepts
- Page 55 and 56:
18 1 Drug Targeting: Basic Concepts
- Page 57 and 58:
20 1 Drug Targeting: Basic Concepts
- Page 59 and 60:
22 1 Drug Targeting: Basic Concepts
- Page 61 and 62:
24 2 Brain-Specific Drug Targeting
- Page 63 and 64:
26 2 Brain-Specific Drug Targeting
- Page 65 and 66:
28 2 Brain-Specific Drug Targeting
- Page 67 and 68:
30 2 Brain-Specific Drug Targeting
- Page 69 and 70:
32 2 Brain-Specific Drug Targeting
- Page 71 and 72:
34 2 Brain-Specific Drug Targeting
- Page 73 and 74:
36 2 Brain-Specific Drug Targeting
- Page 75 and 76:
38 2 Brain-Specific Drug Targeting
- Page 77 and 78:
40 2 Brain-Specific Drug Targeting
- Page 79 and 80:
42 2 Brain-Specific Drug Targeting
- Page 81 and 82:
44 2 Brain-Specific Drug Targeting
- Page 83 and 84:
46 2 Brain-Specific Drug Targeting
- Page 85 and 86:
48 2 Brain-Specific Drug Targeting
- Page 87 and 88:
50 2 Brain-Specific Drug Targeting
- Page 89 and 90:
52 2 Brain-Specific Drug Targeting
- Page 91 and 92:
54 3 Pulmonary Drug Delivery: Deliv
- Page 93 and 94:
56 3 Pulmonary Drug Delivery: Deliv
- Page 95 and 96:
58 3 Pulmonary Drug Delivery: Deliv
- Page 97 and 98:
60 3 Pulmonary Drug Delivery: Deliv
- Page 99 and 100:
62 3 Pulmonary Drug Delivery: Deliv
- Page 101 and 102:
64 3 Pulmonary Drug Delivery: Deliv
- Page 103 and 104:
66 3 Pulmonary Drug Delivery: Deliv
- Page 105 and 106:
68 3 Pulmonary Drug Delivery: Deliv
- Page 107 and 108:
70 3 Pulmonary Drug Delivery: Deliv
- Page 109 and 110:
72 3 Pulmonary Drug Delivery: Deliv
- Page 111 and 112:
74 3 Pulmonary Drug Delivery: Deliv
- Page 113 and 114:
76 3 Pulmonary Drug Delivery: Deliv
- Page 115 and 116:
78 3 Pulmonary Drug Delivery: Deliv
- Page 117 and 118:
80 3 Pulmonary Drug Delivery: Deliv
- Page 119 and 120:
82 3 Pulmonary Drug Delivery: Deliv
- Page 121 and 122:
84 3 Pulmonary Drug Delivery: Deliv
- Page 123 and 124:
86 3 Pulmonary Drug Delivery: Deliv
- Page 125 and 126:
4 Cell Specific Delivery of Anti-In
- Page 127 and 128:
The sinusoids are lined by the disc
- Page 129 and 130:
4.2.2.2 Phagocytosis and Transcytos
- Page 131 and 132:
ther inflammatory cells or accessor
- Page 133 and 134:
4.3 Hepatic Inflammation and Fibros
- Page 135 and 136:
process is not yet available. Sever
- Page 137 and 138:
this carrier to the KCs.When the ma
- Page 139 and 140:
e taken up rapidly by mannose recep
- Page 141 and 142:
y the transcriptional regulatory pr
- Page 143 and 144:
4.8 Testing Liver Targeting Prepara
- Page 145 and 146:
4.8 Testing Liver Targeting Prepara
- Page 147 and 148:
4.9 Targeting of Anti-inflammatory
- Page 149 and 150:
4.9 Targeting of Anti-inflammatory
- Page 151 and 152:
with monoclonal and bispecific anti
- Page 153 and 154: References 117 [50] Coleman DL, Eur
- Page 155 and 156: References 119 [133] Cronstein BN,
- Page 157 and 158: 5 Delivery of Drugs and Antisense O
- Page 159 and 160: 5.1 Introduction 123 convoluted tub
- Page 161 and 162: treatment of the targeted cell and
- Page 163 and 164: CL uptake (ml/min/g) centration pro
- Page 165 and 166: 5.2.1.4 Specific Binding of Alkylgl
- Page 167 and 168: 5.2 Renal Delivery Using Pro-Drugs
- Page 169 and 170: 5.2 Renal Delivery Using Pro-Drugs
- Page 171 and 172: 5.3 Renal Delivery Using Macromolec
- Page 173 and 174: 5.3 Renal Delivery Using Macromolec
- Page 175 and 176: 5.3 Renal Delivery Using Macromolec
- Page 177 and 178: 5.3 Renal Delivery Using Macromolec
- Page 179 and 180: 5.3 Renal Delivery Using Macromolec
- Page 181 and 182: 5.4 Renal Delivary of Antisense Oli
- Page 183 and 184: 5.4 Renal Delivery of Antisense Oli
- Page 185 and 186: 5.4.8 Benefits and Limitations of A
- Page 187 and 188: via reabsorption from the luminal s
- Page 189 and 190: References 153 [66] Franssen EJF, M
- Page 191 and 192: References 155 [145] Van Zwieten PA
- Page 193 and 194: 158 6 A Practical Approach in the D
- Page 195 and 196: 160 6 A Practical Approach in the D
- Page 197 and 198: 162 6 A Practical Approach in the D
- Page 199 and 200: 164 6 A Practical Approach in the D
- Page 201 and 202: 166 6 A Practical Approach in the D
- Page 203: 168 6 A Practical Approach in the D
- Page 207 and 208: 172 7 Vascular Endothelium in Infla
- Page 209 and 210: 174 7 Vascular Endothelium in Infla
- Page 211 and 212: 176 7 Vascular Endothelium in Infla
- Page 213 and 214: 178 7 Vascular Endothelium in Infla
- Page 215 and 216: 180 7 Vascular Endothelium in Infla
- Page 217 and 218: 182 7 Vascular Endothelium in Infla
- Page 219 and 220: 184 7 Vascular Endothelium in Infla
- Page 221 and 222: 186 7 Vascular Endothelium in Infla
- Page 223 and 224: 188 7 Vascular Endothelium in Infla
- Page 225 and 226: 190 7 Vascular Endothelium in Infla
- Page 227 and 228: 192 7 Vascular Endothelium in Infla
- Page 229 and 230: 194 7 Vascular Endothelium in Infla
- Page 231 and 232: 196 7 Vascular Endothelium in Infla
- Page 233 and 234: 8 Strategies for Specific Drug Targ
- Page 235 and 236: 8.2.2 Histogenesis The traditional
- Page 237 and 238: may become obstructed and compresse
- Page 239 and 240: 8.5 Strategies to Deliver Drugs to
- Page 241 and 242: 8.5 Strategies to Deliver Drugs to
- Page 243 and 244: larly cytotoxic immune effector cel
- Page 245 and 246: contributes to limited tumour penet
- Page 247 and 248: ples onto anti-EGP-2 scFv. Biologic
- Page 249 and 250: In the case of drug-monoclonal anti
- Page 251 and 252: cells, the presence of co-stimulato
- Page 253 and 254: Monomethoxy-polyethylene glycol CH
- Page 255 and 256:
e efficiently loaded into the lipos
- Page 257 and 258:
8.6 Clinical Studies 223 Table 8.5.
- Page 259 and 260:
8.6.3 (Synthetic) (co)Polymers Solu
- Page 261 and 262:
8.8 Conclusions and Future Perspect
- Page 263 and 264:
References 229 [43] Chaouchi NA, Va
- Page 265 and 266:
References 231 [126] Czuczman MS, G
- Page 267 and 268:
234 9 Tumour Vasculature Targeting
- Page 269 and 270:
236 9 Tumour Vasculature Targeting
- Page 271 and 272:
238 9 Tumour Vasculature Targeting
- Page 273 and 274:
240 9 Tumour Vasculature Targeting
- Page 275 and 276:
242 9 Tumour Vasculature Targeting
- Page 277 and 278:
244 9 Tumour Vasculature Targeting
- Page 279 and 280:
246 9 Tumour Vasculature Targeting
- Page 281 and 282:
248 9 Tumour Vasculature Targeting
- Page 283 and 284:
250 9 Tumour Vasculature Targeting
- Page 285 and 286:
252 9 Tumour Vasculature Targeting
- Page 287 and 288:
254 9 Tumour Vasculature Targeting
- Page 289 and 290:
256 10 Phage Display Technology for
- Page 291 and 292:
258 10 Phage Display Technology for
- Page 293 and 294:
260 10 Phage Display Technology for
- Page 295 and 296:
262 10 Phage Display Technology for
- Page 297 and 298:
264 10 Phage Display Technology for
- Page 299 and 300:
266 10 Phage Display Technology for
- Page 301 and 302:
268 10 Phage Display Technology for
- Page 303 and 304:
270 10 Phage Display Technology for
- Page 305 and 306:
272 10 Phage Display Technology for
- Page 307 and 308:
11 Development of Proteinaceous Dru
- Page 309 and 310:
carrier is an homogenous product. I
- Page 311 and 312:
11.3 The Homing Device 11.3 The Hom
- Page 313 and 314:
malian cell lines that have acquire
- Page 315 and 316:
jugates for the delivery of other a
- Page 317 and 318:
11.5 The Linkage Between Drug and C
- Page 319 and 320:
actions are directed towards these
- Page 321 and 322:
11.5 The Linkage Between Drug and C
- Page 323 and 324:
homing potential if the antigen rec
- Page 325 and 326:
ly used promoters include T7 RNA po
- Page 327 and 328:
the baculovirus expression vector,
- Page 329 and 330:
11.8 Recombinant DNA Constructs 297
- Page 331 and 332:
11.8 Recombinant DNA Constructs 299
- Page 333 and 334:
toxic activity. Anthrax and tetanus
- Page 335 and 336:
11.9 Recombinant Domains as Buildin
- Page 337 and 338:
References 305 [16] Milstein C, Wal
- Page 339 and 340:
References 307 [99] Verma R, Boleti
- Page 341 and 342:
12 Use of Human Tissue Slices in Dr
- Page 343 and 344:
are also extensively used in a vari
- Page 345 and 346:
Meanwhile many incubation systems h
- Page 347 and 348:
12.3 Incubation and Culture of Live
- Page 349 and 350:
to investigate the effect of differ
- Page 351 and 352:
The mechanisms of uptake and excret
- Page 353 and 354:
12.6 The Use of Liver Slices in Dru
- Page 355 and 356:
12.7 Efficacy Testing of the Drug T
- Page 357 and 358:
NO x µM 80 60 40 20 * * 12.7 Effic
- Page 359 and 360:
TNFα ng/ml 1.5 1 0.5 0 * Human (n=
- Page 361 and 362:
References 329 [33] Ikejima K, Enom
- Page 363 and 364:
References 331 [109] Dutt A, Priebe
- Page 365 and 366:
334 13 Pharmacokinetic/Pharmacodyna
- Page 367 and 368:
336 13 Pharmacokinetic/Pharmacodyna
- Page 369 and 370:
338 13 Pharmacokinetic/Pharmacodyna
- Page 371 and 372:
340 13 Pharmacokinetic/Pharmacodyna
- Page 373 and 374:
342 13 Pharmacokinetic/Pharmacodyna
- Page 375 and 376:
344 13 Pharmacokinetic/Pharmacodyna
- Page 377 and 378:
346 13 Pharmacokinetic/Pharmacodyna
- Page 379 and 380:
348 13 Pharmacokinetic/Pharmacodyna
- Page 381 and 382:
350 13 Pharmacokinetic/Pharmacodyna
- Page 383 and 384:
352 13 Pharmacokinetic/Pharmacodyna
- Page 385 and 386:
354 13 Pharmacokinetic/Pharmacodyna
- Page 387 and 388:
356 13 Pharmacokinetic/Pharmacodyna
- Page 389 and 390:
358 13 Pharmacokinetic/Pharmacodyna
- Page 391 and 392:
360 13 Pharmacokinetic/Pharmacodyna
- Page 393 and 394:
362 13 Pharmacokinetic/Pharmacodyna
- Page 395 and 396:
364 13 Pharmacokinetic/Pharmacodyna
- Page 397 and 398:
366 13 Pharmacokinetic/Pharmacodyna
- Page 399 and 400:
368 13 Pharmacokinetic/Pharmacodyna
- Page 401 and 402:
370 13 Pharmacokinetic/Pharmacodyna
- Page 403 and 404:
372 14 Drug Targeting Strategy: Scr
- Page 405 and 406:
374 14 Drug Targeting Strategy: Scr